Aridol is a specialized diagnostic agent that provides supportive information for the clinical evaluation of respiratory symptoms, assisting with the selection of appropriate management strategies. The product is indicated for the assessment of bronchial hyperresponsiveness (BHR) in patients aged six years and older.

The test is commonly used to support the assessment of symptoms associated with acute or episodic changes, particularly in individuals presenting with persistent coughing, wheezing, or unexplained shortness of breath. This objective information contributes to management decisions in conditions where symptoms may intensify temporarily, providing supportive data for diagnosis.

“The primary benefit of the test is to provide a quantifiable assessment of airway sensitivity that helps guide management.”

The test is applied when assessing suspected asthma, supporting the evaluation of exercise-induced bronchoconstriction (EIB), and monitoring symptomatic control over time. By providing this information, the product assists with management decisions aimed at promoting stability during symptomatic phases.

---

Quick Fact: Support for Diagnosis of Airway Reactivity The test is relevant for supporting the diagnostic process in patients experiencing symptoms that create noticeable physiological strain and symptoms related to heightened physiological activity (BHR).

Eligibility Profile: Official Regulatory Information

Official regulatory documents define the strict population eligibility for Aridol, a diagnostic product, based on age, pulmonary health, and co-morbidities.

Classification	Eligibility Rule (as stated in label)
Populations Allowed	Adults and pediatric patients 6 years of age or older who do not have clinically apparent asthma.
Populations Not Recommended	Children aged 6 to 18 years (limited information) and pregnant individuals (insufficient data to evaluate risk).
Populations Contraindicated	Patients with clinically apparent asthma; very low baseline FEV1 (less than 70% of predicted values); or known hypersensitivity to mannitol or gelatin.

Absolute Contraindications

Use is prohibited in individuals with a history of conditions that may be compromised by induced bronchospasm, including aortic or cerebral aneurysm, recent myocardial infarction or stroke, and uncontrolled hypertension.

Conditional Use Restrictions

The test should be performed with caution in patients with conditions that may increase sensitivity or risk, such as severe cough, unstable angina, active respiratory infection, recent abdominal or thoracic surgery, or renal impairment. Use is not established in the geriatric population.

Interactions with other medicines and products

Since Aridol (mannitol inhalation powder) is a single-use product for diagnostic testing, its documented interaction profile is centered on pharmacodynamic interference that could compromise the accuracy of the test results, rather than systemic drug-drug pharmacokinetic risks.

---

Timing-Based Administration Restrictions

Medicines that reduce airway sensitivity to the bronchial challenge must be withheld for specific mandatory periods before the Aridol test. The requirement to withhold a medicine is based on its duration of action:

• Long-acting Beta2 Agonists (LABAs): Must be withheld for at least 24 hours (including fixed-dose combinations with inhaled corticosteroids).
• Short-acting Beta2 Agonists (SABAs): Must be withheld for at least 8 hours.
• Leukotriene-Receptor Antagonists: Require separation for 4 days.
• Antihistamines (e.g., cetirizine, fexofenadine): Require separation for 72 hours.
• Inhaled Corticosteroids alone may reduce airway sensitivity; a minimum of 12 hours withholding is specified.

Contraindicated Combinations

Administration is formally contraindicated in patients with a known hypersensitivity to the active substance mannitol or to the gelatin used to make the capsules.

Food and Substance Restrictions

Official labeling requires procedural constraints related to ingestion of certain substances before the test:

• Caffeine: Consumption of significant quantities of coffee, tea, cola drinks, and chocolate must be totally avoided on the day of the test as these substances may decrease bronchial responsiveness.
• Vigorous Exercise: Must be avoided for 12 hours before the Aridol test.

Physical Osmotic Stress and Cellular Trigger

The mechanism of inhaled Mannitol (Aridol) is defined by its action as an indirect bronchial challenge agent, limited to the airway surface and bronchial tree. The mechanism begins when the highly soluble powder contacts the Airway Surface Liquid (ASL), creating a localized, powerful hyperosmolar environment. This osmotic imbalance acts as the primary signal, forcing water out of the adjacent airway cells, most importantly the mast cells. This rapid cellular dehydration and shrinkage mechanically triggers the degranulation of these inflammatory cells, initiating the biological sequence.

Inflammatory Mediator Release and Airway Contraction

The triggered degranulation releases pre-formed bronchoconstricting mediators, including Histamine, Prostaglandin D2 ( PGD2), and Cysteinyl Leukotrienes ( CysLTs). These mediators diffuse and bind to their specific receptors on the airway smooth muscle. This cascade facilitates the transmission of a chemical signal to the smooth muscle layer. The receptor-ligand interaction initiates the intracellular signaling that leads to smooth muscle contraction, resulting in a quantifiable bronchoconstriction and temporary airflow limitation. The magnitude of the resultant smooth muscle contraction is directly proportional to the airway's inherent responsiveness to the released mediators.

How to Use Aridol — Official Administration Guidelines

This diagnostic product is utilized strictly as a standardized procedure in a clinical setting.

Administration Scope	Detail
Route of administration	The product is For Oral Inhalation Use Only using the supplied single-use dry powder inhaler. The capsules must not be swallowed.
Dosing schedule	The test utilizes a sequential, stepwise, increasing dose regimen. Nine potential dose steps, starting from 0 mg, lead to a maximum cumulative dose of 635 mg of mannitol if the test endpoint is not reached sooner.
Age-group rules	The entire dosing protocol is the same for adults and pediatric patients aged 6 years and older.
Special procedural conditions	The test must be administered by trained professionals under the supervision of a physician. Patients should refrain from consuming caffeine or undertaking vigorous exercise on the day of the test.

---

Resulting Procedural Structure

The administration of Aridol is defined as a single, intermittent diagnostic event composed of the following regulated sequence:

• Establish Baseline: Standard spirometry must be performed to establish a reproducible baseline FEV1 (Forced Expiratory Volume in 1 second) before the challenge begins.
• Sequential Inhalation: The patient inhales the contents of a capsule in a controlled deep inspiration, followed by a 5-second breath hold; FEV1 is measured 60 seconds after each dose.
• Procedural Stop: The test is stopped when a 15% reduction in FEV1 from baseline or a 10% incremental reduction between doses is observed, or the maximum dose is reached.
• Post-Test Management: Following the test, the patient should receive a standard dose of a short-acting inhaled beta-agonist and be monitored until recovery to near baseline FEV1 levels.

This strictly defined protocol governs the use of the product to ensure the accurate standardization of the bronchial challenge test.

Research evidence / Overview of Studies for Aridol

Evidence for Use in Assessment of Bronchial Hyperresponsiveness (BHR)

The evidence landscape for Aridol includes Phase 3 Randomized Controlled Trials (RCTs) and various systematic reviews. These controlled studies were designed to evaluate the test's diagnostic performance, examining the measurements of bronchial hyperresponsiveness (BHR) in individuals. The studies mostly included patients aged 6 years and older who were referred for BHR assessment because they were experiencing outcomes related to episodic or acute changes like unexplained coughing or wheezing.

Research has primarily examined a functional measure known as the percent decrease in Forced Expiratory Volume in 1 second (FEV1). The primary outcome examined was how this functional measure changed immediately after the test was administered. Studies examined the test's agreement (sensitivity and specificity) relative to the results of other challenge methods, used as reference standards. These reported outcomes reflect acute physiological responses observed in the populations studied.

However, the research results apply only to the populations studied. The current evidence is restricted, as the clinical trials intentionally excluded people who already had a confirmed diagnosis of clinically apparent asthma or those with very low baseline lung function. Therefore, the findings do not provide insight into the test's reliability or use in subjects with very severe or unstable respiratory conditions.

Comparative Studies for Exercise-Induced Bronchoconstriction (EIB)

Research has explored the utility of the Aridol test in assessing potential Exercise-Induced Bronchoconstriction (EIB). These studies involved various comparative designs to evaluate how results from the Aridol test aligned with the results of the standard exercise challenge test, which is often used as a comparator for EIB assessment. Comparative trials reported that the test was associated with similar physiological changes when compared to those seen with the standard exercise challenge.

What Remains Uncertain and Areas for Future Research

The primary research for Aridol, which informed its authorized diagnostic indication, is based on the acute response immediately following the inhalation. Consequently, data exploring long-term effects are not well characterized. The acute findings describe group patterns, but it is not yet clear how these test results relate to stability or change in outcomes reflecting daily functioning or activity level over an extended period. Research is also limited concerning whether the test provides comparable diagnostic information relative to established challenge tests.

Common questions about Aridol (FAQ)

Q: How is the Aridol test different from a standard spirometry test?

The Aridol test is a specialized diagnostic bronchial challenge, distinct from standard spirometry. Standard spirometry is used to establish a patient's baseline lung function. The Aridol challenge then provokes a small, measurable change in breathing function to assess if the patient's airways are hyperresponsive.

Q: What is the difference between Aridol and Methacholine challenge tests?

Aridol is classified as an indirect bronchial challenge agent because it works by triggering the release of natural chemicals already in the airways. In contrast, other challenge agents, such as Methacholine, work by a different, direct mechanism. Official information indicates that clinical studies have been conducted to compare Aridol's diagnostic performance to that of the Methacholine challenge.

Q: How quickly does Aridol cause an effect on the airways?

The Aridol test procedure involves taking measurements of the patient's breathing function (FEV1) very rapidly after each dose. The official administration instructions require the FEV1 measurement be taken 60 seconds after inhalation of the dose of Aridol.

Q: Is it normal to cough or feel throat irritation during the Aridol test?

Cough is listed as a Very Common adverse reaction, reported in more than 1 in 10 patients. Throat irritation and soreness are also classified as Common reactions. Because the test is designed to provoke a physiological response, these reactions are common according to clinical data.

Q: Does Aridol cause long-term side effects after the test is over?

The product is designed as an acute diagnostic test, and adverse reactions reported in the official documentation are those that occur during the procedure or within one day thereafter. The official product documentation, which focuses on acute diagnostic use, does not contain information on long-term effects beyond the testing period.

Q: Can a patient with a recent respiratory infection still take the Aridol test?

The official label advises that the test should be performed with caution in patients who have an active upper or lower respiratory tract infection. This is due to the potential for an active infection to increase the sensitivity of the airways during the procedure.

Q: Do I need to stop taking my allergy medication before the Aridol test?

The official label requires that certain medications be withheld for specific periods before the test. This withholding is necessary because these medicines, such as antihistamines, may reduce airway sensitivity and affect the test's accuracy.

Q: Does Aridol help determine the severity of a patient's breathing issues?

Aridol is officially indicated for the assessment of bronchial hyperresponsiveness (BHR). The test’s primary function, as indicated in the label, is to quantify a patient's airway reactivity. The result is a key measurement used by physicians in the broader clinical assessment.

Q: How reproducible are the results of an Aridol test if it needs to be repeated?

Clinical studies referenced in the official prescribing information evaluate the test's diagnostic performance (sensitivity and specificity). The test is administered using a strictly standardized and defined protocol, which is designed to provide controlled and accurate measurements.

Q: Are there other medications similar to Aridol used for bronchial challenges?

Aridol is an indirect bronchial challenge agent. Official information shows that its performance has been evaluated against other challenge methods, including the Methacholine challenge and the Exercise challenge.

Q: Can Aridol interact with common over-the-counter pain relievers?

The documented interaction profile focuses on medicines that could interfere with the test procedure itself, such as respiratory and allergy medications. Since Aridol is a single-use diagnostic agent, the official label does not specifically address systemic drug-drug interactions with common pain relievers.

Q: Are there reasons why the Aridol test might be inconclusive or inaccurate?

The test's results could be inaccurate if required withholding times for certain medications are not followed. Furthermore, the test is designed to be performed only when the patient meets specific criteria, such as an adequate baseline lung function.

Q: What are the ingredients in Aridol besides mannitol?

The product is composed of the active ingredient Mannitol inhalation powder, which is supplied in gelatin capsules. The capsule shells themselves contain non-medicinal ingredients, such as coloring agents like titanium dioxide and iron oxides.

Q: Does Aridol contain any allergens, such as lactose or gluten?

Official labeling states the product must not be used (is contraindicated) if a patient has a known hypersensitivity to the active substance mannitol or to the gelatin used to make the capsules. Other common allergens like lactose or gluten are not specifically listed as contraindications in the official label.

Q: Is Aridol the same drug as the one used for cystic fibrosis maintenance treatment (Bronchitol)?

While the active ingredient is the same (mannitol inhalation powder), Aridol is specifically indicated as a diagnostic test for bronchial hyperresponsiveness. Other inhalation products containing mannitol may be authorized for chronic conditions, such as the maintenance treatment of cystic fibrosis.

Q: Does Aridol cause severe breathing problems, and what happens if it does?

Because the test is designed to provoke a response, Severe Bronchospasm is the most significant safety consideration. The official protocol requires that a rescue medication, a short-acting inhaled beta-agonist, be administered immediately if a positive test response is reached or if severe symptoms occur. The patient is then monitored until breathing function stabilizes.

Q: Is the Aridol test appropriate for older adults?

Official information states that appropriate studies have not been performed specifically for the older adult population. Therefore, the safety and efficacy have not been established in this age group.

Q: Can Aridol be used during pregnancy or while breastfeeding?

Official data on the use of Aridol in pregnant women is limited. It is generally recommended only when a physician determines the potential benefits outweigh the potential risks. It is also unknown whether mannitol passes into breast milk, and caution is advised for nursing women.

Q: What is the role of the 0 mg capsule at the beginning of the test?

The 0 mg capsule is the first step in the sequential inhalation process. The FEV1 measurement taken after this step is used to establish the patient's baseline FEV1 before the active drug is administered.

Q: Can the Aridol inhaler device be reused for later tests?

No, the Aridol kit is supplied with a single patient use dry powder inhaler device. The official instructions specify that the inhaler, along with all unused capsules, should be discarded immediately upon completion of the test.

Q: What are the chances of experiencing a headache after the Aridol test?

Clinical trial data classifies Headache as a Common adverse reaction, meaning it was reported in up to 10% of patients during the testing period.

Q: Do people sometimes feel nauseous or dizzy after completing the test?

Nausea is reported as a Common adverse reaction (occurring in up to 10% of patients). Dizziness is reported as a less common reaction, occurring in less than 1% of patients.

Q: What happens if a patient accidentally swallows the Aridol capsule contents?

Official product information states that the capsules must not be swallowed and that the product is for oral inhalation use only. The label does not detail specific adverse consequences for accidental ingestion.

Q: Is Aridol used to diagnose Exercise-Induced Bronchoconstriction (EIB)?

Aridol is officially indicated for the assessment of bronchial hyperresponsiveness (BHR). Clinical studies referenced in the official label have evaluated the test’s performance against the standard exercise challenge test.

Q: Is the Aridol challenge test considered more standardized than an exercise challenge test?

Official regulatory documents do not state that one test is 'more standardized' than the other. However, the Aridol test is described as following a strictly defined protocol for its inhalation and spirometry measurements.

Q: What is the general wait time after a positive Aridol test before being treated with a rescue inhaler?

The official protocol requires that a rescue medication, such as a short-acting inhaled beta-agonist, is administered immediately if a patient shows a positive test response or experiences significant symptoms. The patient is then monitored until breathing function stabilizes.

Storing and Disposing of Aridol (Mannitol Inhalation Powder)

Aridol must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The product must be protected from extreme temperatures; do not freeze or refrigerate the test kit.

---

Packaging and Protection

The capsules must remain in their consecutively numbered foil blister packs until immediately prior to use to protect the inhalation powder from moisture and environmental factors. The product is supplied as a single patient use bronchial challenge test kit.

---

Disposal Instructions

Following the completion of the test, all remaining unused (opened and unopened) blister packs and the inhaler must be properly discarded according to official instructions. This ensures safe handling as defined by the product's regulatory labeling.